secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVANOS MEDICAL, INC. (AVNS)
CIK:        0001606498
Form:       8-K
Filed at:   2021-08-03T23:59:59+00:00
Accession:  0001606498-21-000046
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avanos Q2 net sales $186M (+14% YoY); guides FY adj. EPS to $1.10–$1.20 from $1.10–$1.25
--------------------------------------------------------------------------------

- Q2 diluted EPS $0.78 vs. loss of $0.06; adjusted diluted EPS $0.21 vs. $0.13.
- Gross margin fell to 46% (59% adj.) due to higher freight and manufacturing inefficiencies.
- Full-year net sales growth outlook maintained at 2%–4% constant currency; adj. EPS guidance narrowed to $1.10–$1.20.
- Entered Deferred Prosecution Agreement with DOJ on July 6 resolving criminal investigation into MicroCool surgical gowns.
- Board member Heidi Kunz resigned July 29 to pursue other opportunities; no disagreements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1606498/000160649821000046/0001606498-21-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1606498/000160649821000046/avns-20210729.htm
  HTML page:      https://secwatch.observer/filing/0001606498-21-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer